33 / 43
Long-Term Overall Survival
Study
Median OS, Months
(95% CI)
Phase
1
22.4 (12.5–NE)
Phase
2
23.4 (17.7–26.9)
Minimum follow-up: 50.5 months (CA209-003) and 49.2 months (CA209-010); reported as of June 2016.
CI, confidence interval; NE, not estimable; OS, overall survival.
McDermott DF et al. Oral presentation at ASCO 2016. 4507.
CA209-003: monotherapy
CA209-010: monotherapy
34 28 24 18 14 13 12 12 11 8 6 6 2 1 0
167 142 113 93 80 65 58 51 47 2 0 0 0 0 0
No. of patients at risk
Phase 1
Phase 2
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84
Overall Survival (Probability)
Months
38%
29%
34%